Drug eruption caused by recombinant human G-CSF

Intern Med. 1994 Oct;33(10):641-3. doi: 10.2169/internalmedicine.33.641.


Two types of recombinant human granulocyte colony-stimulating factor (rhG-CSF) are available, and equally used for mitigation of neutropenia. One is a glycosylated natural product from mammalian cells, and the other a non-glycosylated form from Escherichia coli. Though only minimal adverse effects have been reported for both, we treated two patients with rhG-CSF-induced systemic eruption. Based on these patients, the following should be noted: 1) drug eruption may occur in both types of rhG-CSF without detectable antibodies, 2) intradermal test is useful for determination of the causal drug, and 3) if one rhG-CSF product causes eruption, the alternative one may possibly be safe and effective.

Publication types

  • Case Reports

MeSH terms

  • Adjuvants, Immunologic / adverse effects
  • Adjuvants, Immunologic / therapeutic use
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Drug Eruptions / etiology*
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor / adverse effects*
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Intradermal Tests
  • Lenograstim
  • Lung Neoplasms / drug therapy
  • Male
  • Neutropenia / chemically induced
  • Neutropenia / therapy
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use


  • Adjuvants, Immunologic
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Lenograstim
  • Filgrastim